Insider Cluster (2 insiders) ·Filed Jun 15, 2026

RARE

Ultragenyx Pharmaceutical Inc.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago
Insider cluster: 2 insiders, $97K total
Actionable Insight • Neutral

The cluster is too small to warrant a trade signal. Monitor for any material insider buying or a larger sell cluster (>0.5% of market cap) that would indicate a change in sentiment. The company's next catalyst is likely pipeline updates or earnings — no immediate read-through from these sales.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
RARE ▼ -42.05% at T+60d
NEUTRAL call ✗ call lost -42.05% · α vs SPY -43.05% · entry $24.85 → $14.40
Entry anchored
Jun 15, 03:59 PM ET
via exchange tick
T+1d
+8.29%
call +8.29% · α +9.54%
$26.91
settled 4mo ago
T+5d
+15.73%
call +15.73% · α +17.97%
$28.76
settled 3mo ago
T+20d
+28.89%
call +28.89% · α +28.69%
$32.03
settled 3mo ago
T+60d
-42.05%
call -42.05% · α -43.05%
$14.40
settled 22d ago

Price Chart

Loading chart...

Executive Summary

Two insiders at Ultragenyx sold a combined $97K in open-market transactions on June 15, 2026. The EVP/Chief Legal Officer and a Director each sold modest amounts, representing ~0.004% of the company's $2.4B market cap. The sales are trivial in size and likely routine portfolio adjustments, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$96.9K
Insiders
2

Key Facts

  • Two insiders sold shares on June 15, 2026: EVP/Chief Legal Officer sold 1,899 shares ($47K) and a Director sold 2,000 shares ($50K).
  • Total open-market sales of $97K represent ~0.004% of RARE's $2.4B market cap.
  • No C-suite executives (CEO, CFO, COO) participated in the cluster.
  • Recent 30-day insider activity shows 4 prior sells totaling $352K, consistent with routine liquidity-driven selling.

Financial Impact

Total insider sales of $97K, immaterial relative to $2.4B market cap.

insider ownership

Risk Factors

  • Insider sales could accelerate if management anticipates negative clinical or regulatory news.
  • The company's high institutional ownership (88% bullish consensus) may mask insider bearishness if sales grow in size.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (25 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-RARE-1781563885174
12 reports for RARE
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +48.73%Apr 2, 2026
Filters
Rows
Reports for RARE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BEARISH ★ 8/10
$14.85 $15.22▼ −2.49%▼ −3.68%$15.22 (−2.49%)
Sep 1, 2026
4w ago
Press Release
BULLISH ★ 7/10
$26.53 $15.03▼ −43.35%▼ −43.02%$15.22 (−42.63%)
Aug 11, 2026
7w ago
8-K
NEUTRAL ★ 4/10
$26.80 $14.31▼ −46.60%▼ −45.55%$15.22 (−43.21%)
Aug 4, 2026
8w ago
8-K
BULLISH ★ 6/10
$24.93 $26.53▲ +6.42%▲ +7.02%$15.22 (−38.95%)
Aug 4, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$25.81 $25.81· 0.00%▲ +1.24%$15.22 (−41.03%)
Jun 15, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.85 $32.03▲ +28.89%▲ +28.69%$15.22 (−38.75%)
Jun 11, 2026
16w ago
Institutional Cluster
NEUTRAL ★ 4/10
$23.98 $34.61▲ +44.33%▲ +42.44%$15.22 (−36.53%)
May 5, 2026
21w ago
Press Release
BEARISH ★ 6/10
$25.93 $22.41▲ +13.57%▲ +16.36%$15.22 (+41.30%)
May 1, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.77 $22.85▼ −7.75%▼ −13.04%$15.22 (−38.55%)
Apr 2, 2026
26w ago
8-K
BULLISH ★ 8/10
$22.45 $24.69▲ +9.98%▲ +0.10%$15.22 (−32.20%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (38h 30m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jun 15, 2026